• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Changes in the etiology of liver cirrhosis and the corresponding management strategies.肝硬化病因的变化及相应的管理策略。
World J Hepatol. 2024 Feb 27;16(2):146-151. doi: 10.4254/wjh.v16.i2.146.
2
Study of liver cirrhosis over ten consecutive years in Southern China.中国南方地区连续十年肝硬化研究。
World J Gastroenterol. 2014 Oct 7;20(37):13546-55. doi: 10.3748/wjg.v20.i37.13546.
3
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病驱动的肝细胞癌的药物治疗
Front Pharmacol. 2024 Jan 19;14:1336216. doi: 10.3389/fphar.2023.1336216. eCollection 2023.
4
The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.日本全国性调查中肝细胞癌合并肝硬化病因的转变。
J Gastroenterol. 2021 Feb;56(2):158-167. doi: 10.1007/s00535-020-01748-x. Epub 2020 Nov 20.
5
Overview of Complications in Cirrhosis.肝硬化并发症概述
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14.
6
Study of liver cirrhosis over twenty consecutive years in adults in Southern China.中国南方成年人肝硬化连续二十年研究。
World J Hepatol. 2023 Dec 27;15(12):1294-1306. doi: 10.4254/wjh.v15.i12.1294.
7
Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019.代谢功能障碍相关脂肪性肝病正成为中国肝硬化负担的主要驱动因素:2019年全球疾病负担研究结果
J Clin Gastroenterol. 2024 Aug 5. doi: 10.1097/MCG.0000000000002055.
8
Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.MASLD 伴肝细胞癌的家族聚集性及不良肝脏结局:全国多代队列研究。
J Hepatol. 2023 Dec;79(6):1374-1384. doi: 10.1016/j.jhep.2023.08.018. Epub 2023 Aug 28.
9
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.肝癌潜在病因及其对治疗结果影响的观点
J Hepatocell Carcinoma. 2023 Mar 10;10:413-428. doi: 10.2147/JHC.S347959. eCollection 2023.
10
Hepatitis-C-Related Hepatocellular Carcinoma, Still a Relevant Etiology beyond a Hepatitis C Infection Cure.丙型肝炎相关肝细胞癌:即使丙型肝炎感染已治愈,仍是一个相关病因
Cancers (Basel). 2024 Apr 16;16(8):1521. doi: 10.3390/cancers16081521.

引用本文的文献

1
The Niemann-Pick C1 Protein of Patients with Hepatocellular Carcinoma Is Associated with Survival Time in Males and Tumor Size in Females.肝细胞癌患者的尼曼-匹克C1蛋白与男性的生存时间及女性的肿瘤大小相关。
Biomedicines. 2025 Jul 13;13(7):1707. doi: 10.3390/biomedicines13071707.
2
Unlocking the therapeutic potential of unexplored phytocompounds as hepatoprotective agents through integration of network pharmacology and in-silico analysis.通过整合网络药理学和计算机模拟分析,挖掘未被探索的植物化合物作为肝保护剂的治疗潜力。
Sci Rep. 2025 Mar 11;15(1):8425. doi: 10.1038/s41598-025-92868-y.

本文引用的文献

1
Study of liver cirrhosis over twenty consecutive years in adults in Southern China.中国南方成年人肝硬化连续二十年研究。
World J Hepatol. 2023 Dec 27;15(12):1294-1306. doi: 10.4254/wjh.v15.i12.1294.
2
Autoimmune Hepatitis: Epidemiology, Subtypes, and Presentation.自身免疫性肝炎:流行病学、亚型和表现。
Clin Liver Dis. 2024 Feb;28(1):1-14. doi: 10.1016/j.cld.2023.06.002. Epub 2023 Aug 17.
3
Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023).全球非酒精性脂肪性肝病治疗的趋势和热点:文献计量学和可视化分析(2010-2023)。
World J Gastroenterol. 2023 Oct 7;29(37):5339-5360. doi: 10.3748/wjg.v29.i37.5339.
4
Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019.欧洲的乙型肝炎和丙型肝炎:来自 2019 年全球疾病负担研究的最新更新。
Lancet Public Health. 2023 Sep;8(9):e701-e716. doi: 10.1016/S2468-2667(23)00149-4.
5
Overview and countermeasures of cancer burden in China.中国癌症负担概述及对策。
Sci China Life Sci. 2023 Nov;66(11):2515-2526. doi: 10.1007/s11427-022-2240-6. Epub 2023 Apr 13.
6
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
7
Contemporary Epidemiology of Primary Biliary Cholangitis.原发性胆汁性胆管炎的当代流行病学。
Clin Liver Dis. 2022 Nov;26(4):555-570. doi: 10.1016/j.cld.2022.06.001. Epub 2022 Sep 11.
8
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.
9
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
10
The transition of alcohol control in China 1990-2019: Impacts and recommendations.中国 1990-2019 年酒精控制的转变:影响与建议。
Int J Drug Policy. 2022 Jul;105:103698. doi: 10.1016/j.drugpo.2022.103698. Epub 2022 Apr 26.

肝硬化病因的变化及相应的管理策略。

Changes in the etiology of liver cirrhosis and the corresponding management strategies.

作者信息

Dai Jin-Jin, Liu Yue-Ying, Zhang Zhen-Hua

机构信息

Department of Infectious Diseases, Suzhou Hospital of Anhui Medical University, Suzhou 234000, Anhui Province, China.

Department of Infectious Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui Province, China.

出版信息

World J Hepatol. 2024 Feb 27;16(2):146-151. doi: 10.4254/wjh.v16.i2.146.

DOI:10.4254/wjh.v16.i2.146
PMID:38495283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10941737/
Abstract

We read with interest the article by Xing Wang, which was published in the recent issue of the 2023; 15: 1294-1306. This article focuses particularly on the prevalence and trends in the etiology of liver cirrhosis (LC), prognosis for patients suffering from cirrhosis-related complications and hepatocellular carcinoma (HCC), and management strategies. The etiology of cirrhosis varies according to geographical, economic, and population factors. Viral hepatitis is the dominant cause in China. Vaccination and effective treatment have reduced the number of people with viral hepatitis, but the overall number is still large. Patients with viral hepatitis who progress over time to LC and HCC remain an important population to manage. The increased incidence of metabolic syndrome and alcohol consumption is likely to lead to a potential exponential increase in metabolic dysfunction-associated steatotic liver disease (MASLD)-associated LC and alcoholic liver disease in the future. Investigating the evolution of the etiology of LC is important for guiding the direction of future research and policy development. These changing trends indicate a need for greater emphasis on tackling obesity and diabetes, and implementing more effective measures to regulate alcohol consumption in order to reduce the occurrence of MASLD. In an effort to help cope with these changing trends, the authors further proposed countermeasures for healthcare authorities doctors, and patients.

摘要

我们饶有兴趣地阅读了王兴发表在最近一期《2023;15:1294 - 1306》上的文章。本文特别关注肝硬化(LC)病因的流行情况和趋势、肝硬化相关并发症和肝细胞癌(HCC)患者的预后以及管理策略。肝硬化的病因因地理、经济和人口因素而异。在中国,病毒性肝炎是主要病因。疫苗接种和有效治疗已减少了病毒性肝炎患者的数量,但总体数量仍然很大。随着时间推移进展为LC和HCC的病毒性肝炎患者仍是需要管理的重要人群。代谢综合征和酒精消费的增加可能会导致未来代谢功能障碍相关脂肪性肝病(MASLD)相关的LC和酒精性肝病潜在呈指数增长。研究LC病因的演变对于指导未来研究方向和政策制定很重要。这些不断变化的趋势表明需要更加重视解决肥胖和糖尿病问题,并采取更有效的措施来规范酒精消费,以减少MASLD的发生。为了帮助应对这些不断变化的趋势,作者进一步为卫生当局、医生和患者提出了对策。